Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 2 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Recs

0
Player Avatar NuclearSteve (< 20) Submitted: 12/28/2011 2:27:39 PM : Outperform Start Price: $8.38 NBIX Score: -28.05

Very bullish chart pattern and bullish articles are chances for their endometriosis drug.

Featured Broker Partners


Advertisement